TIDMC4XD

RNS Number : 0552A

C4X Discovery Holdings PLC

18 January 2024

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Board Change

18 January 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that Mario Polywka, Non-Executive Director, has stepped down from the Board of Directors with immediate effect in order to focus on his recent appointment as Interim Chief Executive Officer of Evotec SE.

The Company intends to appoint a replacement Non-Executive Director and a further announcement will be made in due course.

Clive Dix, Interim Executive Chairman and Chief Executive Officer of C4X Discovery, said : "It has been a pleasure working with Mario since he joined the Board in 2021 and during this time C4X Discovery has benefitted from his deep industry insights and experience. We wish him all the best in his new role."

- Ends -

Contacts

 
 C4X Discovery Holdings 
 Mo Noonan, Communications                    +44 (0)787 6444977 
 
 Panmure Gordon (UK) Limited (NOMAD and 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate 
  Finance)                                    +44 (0)20 7886 2500 
 Rupert Dearden (Corporate Broking) 
 
 C4X Discovery Media - ICR Consilium 
 Mary-Jane Elliott, Chris Gardner, Matthew 
  Neal                                        +44 (0)203 709 5700 
 C4X Discovery Holdings

Notes to Editors:

About C4X Discovery

C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world--leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. We are advancing our internal portfolio which ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.

For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAQDLFFZFLZBBL

(END) Dow Jones Newswires

January 18, 2024 02:00 ET (07:00 GMT)

C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more C4x Discovery Charts.
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more C4x Discovery Charts.